Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer

EJNMMI Research

Table 1 Patient characteristics

Patient	Tumor site	Histologic subtype	Differentiation	TNM	IAZGP (MBq)	Imaging scheme	IAZGP uptake	Neoadjuvant therapy	Response (%)
1	Pseudomyxoma peritonei	Mucinous adenocarcinoma	Moderate	N/A	116	A	(-)	None	N/A
2	Tonsil	Squamous	Moderate to poor	cT₁N₂M₀	108	A	(-)	Radiation	NED
3	Tonsil	Squamous	Poor	cT₄N₂M₀	59	A	(-)	CRT	NED
4	Tongue	Squamous	Poor	cT₁N₁M₀	160	B	(-)	CRT	NED
5	Rectum	Mucinous adenocarcinoma	Poor	pT₄N₂M₀	148	B	(-)	CRT	95%
6	Rectum	Adenocarcinoma	Moderate	pT₃N₀M₁	141	B	(-)	Chemotherapy	50%
7	Rectum	Adenocarcinoma	Moderate	pT₃N₀M₀	150	B	(-)	CRT	60%
8	Rectum	Adenocarcinoma	Moderate	cT₄NxM₁	159	B	(-)	Chemotherapy	Progression
9	Supraglottic larynx	Squamous	Moderate	cT₃N₂M₀	157	B	(-)	CRT	NED
10	Sigmoid	Adenocarcinoma	Moderate	cTxN₂M₁	159	B	(-)	Chemotherapy	Progression

Serial whole-body, blood, and PET data were acquired for patients 1 to 10. Post-imaging clinical management and response are also shown. CRT chemoradiotherapy, NED no evidence of disease. Imaging schemes: A = 3, 18 to 24, and 48 h post ¹²⁴I-IAZGP injection; B = 3, 6 to 8, and 24 h post ¹²⁴I-IAZGP injection.